AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Tagrisso (osimertinib) by Year
Tagrisso (osimertinib) — Established RoW product sales ($M) ($M)
AstraZeneca Tagrisso (osimertinib): $796M in FY2025, up 4.6% from a year earlier.
Latest, FY2025
796
Period ended Dec 31, 2025
Change on a year earlier
+4.6%
761 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Tagrisso | 7,254 | 10 | 10 | 3,064 | 11 | 1,971 | 12 | 14 | 1,423 | 9 | 6 | 796 | 5 | 5”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tagrisso (osimertinib) — Established RoW product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 796 | +4.6% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 761 | -2.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 782 | -7.7% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 847 | -7.2% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 913 | +13.3% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 806 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up tagrisso (osimertinib)
Cite this data
StockData. (2026). AstraZeneca Tagrisso (osimertinib) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tagrisso-erow
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.